NBY
Income statement / Annual
Last year (2024), NovaBay Pharmaceuticals, Inc.'s total revenue was $9.78 M,
a decrease of 6.45% from the previous year.
In 2024, NovaBay Pharmaceuticals, Inc.'s net income was -$7.22 M.
See NovaBay Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$9.78 M |
$10.46 M |
$14.40 M |
$10.20 M |
$9.93 M |
$6.60 M |
$12.51 M |
$18.23 M |
$11.90 M |
$4.38 M |
| Cost of Revenue |
$3.30 M
|
$4.37 M
|
$6.62 M
|
$3.69 M
|
$3.97 M
|
$1.74 M
|
$1.50 M
|
$2.78 M
|
$2.46 M
|
$1.26 M
|
| Gross Profit |
$6.48 M
|
$6.08 M
|
$7.78 M
|
$6.52 M
|
$5.96 M
|
$4.86 M
|
$11.01 M
|
$15.45 M
|
$9.43 M
|
$3.12 M
|
| Gross Profit Ratio |
0.66
|
0.58
|
0.54
|
0.64
|
0.6
|
0.74
|
0.88
|
0.85
|
0.79
|
0.71
|
| Research and Development Expenses |
$42.00 K
|
$34.00 K
|
$174.00 K
|
$44.00 K
|
$285.00 K
|
$184.00 K
|
$259.00 K
|
$410.00 K
|
$1.37 M
|
$6.05 M
|
| General & Administrative Expenses |
$7.38 M
|
$5.45 M
|
$7.49 M
|
$7.24 M
|
$5.93 M
|
$5.31 M
|
$5.83 M
|
$8.64 M
|
$7.24 M
|
$8.01 M
|
| Selling & Marketing Expenses |
$4.03 M
|
$4.71 M
|
$7.80 M
|
$8.09 M
|
$6.17 M
|
$8.77 M
|
$12.79 M
|
$13.71 M
|
$11.81 M
|
$10.52 M
|
| Selling, General & Administrative Expenses |
$11.41 M
|
$10.15 M
|
$15.29 M
|
$15.33 M
|
$12.11 M
|
$14.08 M
|
$18.62 M
|
$22.35 M
|
$19.04 M
|
$18.53 M
|
| Other Expenses |
$865.00 K
|
$0.00
|
$6.74 M
|
$0.00
|
$0.00
|
$0.00
|
$19.00 K
|
$12.00 K
|
-$68.00 K
|
-$96.00 K
|
| Operating Expenses |
$12.32 M
|
$10.19 M
|
$22.20 M
|
$15.38 M
|
$12.39 M
|
$14.26 M
|
$18.88 M
|
$22.76 M
|
$20.42 M
|
$24.13 M
|
| Cost And Expenses |
$15.62 M
|
$14.56 M
|
$28.82 M
|
$19.07 M
|
$16.36 M
|
$16.00 M
|
$20.38 M
|
$25.54 M
|
$22.88 M
|
$25.40 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$904.00 K
|
$1.69 M
|
$0.00
|
$0.00
|
$0.00
|
$1.05 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$381.00 K
|
$356.00 K
|
$483.00 K
|
$119.00 K
|
$51.00 K
|
$65.00 K
|
$266.00 K
|
$95.00 K
|
$114.00 K
|
$164.00 K
|
| EBITDA |
-$5.93 M |
-$4.10 M |
-$7.20 M |
-$8.74 M |
-$6.38 M |
-$9.34 M |
-$7.61 M |
-$7.22 M |
-$10.87 M |
-$20.97 M |
| EBITDA Ratio |
-0.61
|
-0.39
|
-0.5
|
-0.86
|
-0.64
|
-1.41
|
-0.61
|
-0.4
|
-0.91
|
-4.79
|
| Operating Income Ratio |
-0.6
|
-0.39
|
-1
|
-0.87
|
-0.65
|
-1.42
|
-0.63
|
-0.4
|
-0.92
|
-4.8
|
| Total Other Income/Expenses Net |
-$1.37 M
|
-$2.04 M
|
$3.81 M
|
$3.04 M
|
-$4.61 M
|
-$252.00 K
|
$1.33 M
|
-$89.00 K
|
-$2.17 M
|
$2.04 M
|
| Income Before Tax |
-$7.21 M
|
-$6.15 M
|
-$10.61 M
|
-$5.82 M
|
-$11.03 M
|
-$9.65 M
|
-$6.54 M
|
-$7.40 M
|
-$13.15 M
|
-$18.97 M
|
| Income Before Tax Ratio |
-0.74
|
-0.59
|
-0.74
|
-0.57
|
-1.11
|
-1.46
|
-0.52
|
-0.41
|
-1.11
|
-4.33
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.00 K
|
$6.00 K
|
$4.00 K
|
$3.00 K
|
$2.00 K
|
$12.00 K
|
| Net Income |
-$7.22 M
|
-$9.64 M
|
-$10.61 M
|
-$5.82 M
|
-$11.04 M
|
-$9.66 M
|
-$6.55 M
|
-$7.40 M
|
-$13.15 M
|
-$18.97 M
|
| Net Income Ratio |
-0.74
|
-0.92
|
-0.74
|
-0.57
|
-1.11
|
-1.46
|
-0.52
|
-0.41
|
-1.11
|
-4.33
|
| EPS |
-2.53 |
-139.14 |
-353.59 |
-184.09 |
-385.53 |
-593.63 |
-473.83 |
-591.81 |
-1058.69 |
-702.47 |
| EPS Diluted |
-2.53 |
-138.65 |
-353.59 |
-184.09 |
-385.53 |
-593.63 |
-564.17 |
-591.81 |
-1047.97 |
-694.63 |
| Weighted Average Shares Out |
$3.40 M
|
$120.00 K
|
$30.00 K
|
$31.64 K
|
$28.63 K
|
$16.27 K
|
$11.60 K
|
$12.51 K
|
$12.42 K
|
$27.01 K
|
| Weighted Average Shares Out Diluted |
$3.40 M
|
$120.00 K
|
$46.00 K
|
$35.63 K
|
$28.63 K
|
$17.67 K
|
$13.93 K
|
$12.51 K
|
$12.55 K
|
$27.31 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
